Zacks Research Has Negative Forecast for CORT Q3 Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Equities researchers at Zacks Research reduced their Q3 2026 earnings per share (EPS) estimates for shares of Corcept Therapeutics in a note issued to investors on Wednesday, January 14th. Zacks Research analyst Team now forecasts that the biotechnology company will post earnings of $0.30 per share for the quarter, down from their previous estimate of $0.32. Zacks Research currently has a “Strong Sell” rating on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q4 2026 earnings at $0.49 EPS, Q1 2027 earnings at $0.48 EPS, Q2 2027 earnings at $0.57 EPS, Q3 2027 earnings at $0.87 EPS, Q4 2027 earnings at $1.29 EPS and FY2027 earnings at $3.21 EPS.

Several other research firms also recently commented on CORT. Wall Street Zen downgraded shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, October 18th. Wolfe Research lowered Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 target price for the company. in a report on Wednesday, December 31st. Canaccord Genuity Group cut their price target on Corcept Therapeutics from $140.00 to $99.00 and set a “buy” rating on the stock in a report on Friday, January 2nd. HC Wainwright reduced their price target on Corcept Therapeutics from $145.00 to $90.00 and set a “buy” rating on the stock in a research report on Friday, January 2nd. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Corcept Therapeutics in a research report on Monday, December 29th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $80.83.

Corcept Therapeutics Trading Down 4.5%

Shares of CORT stock opened at $35.39 on Friday. Corcept Therapeutics has a fifty-two week low of $32.99 and a fifty-two week high of $117.33. The company has a 50 day moving average price of $69.87 and a 200 day moving average price of $72.49. The stock has a market capitalization of $3.72 billion, a P/E ratio of 40.22 and a beta of 0.23. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.07 and a current ratio of 3.14.

Corcept Therapeutics (NASDAQ:CORT) last released its earnings results on Tuesday, November 4th. The biotechnology company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.02). The firm had revenue of $207.64 million during the quarter, compared to analyst estimates of $223.78 million. Corcept Therapeutics had a net margin of 14.19% and a return on equity of 15.99%. The business’s revenue was up 13.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.41 earnings per share.

Insiders Place Their Bets

In other news, CEO Joseph K. Belanoff sold 40,000 shares of the firm’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $79.77, for a total transaction of $3,190,800.00. Following the sale, the chief executive officer owned 2,701,370 shares of the company’s stock, valued at approximately $215,488,284.90. This trade represents a 1.46% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Joseph Douglas Lyon sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $73.65, for a total value of $368,250.00. Following the sale, the insider owned 10,277 shares of the company’s stock, valued at approximately $756,901.05. The trade was a 32.73% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 194,500 shares of company stock worth $14,186,410. Insiders own 20.80% of the company’s stock.

Hedge Funds Weigh In On Corcept Therapeutics

Several hedge funds have recently made changes to their positions in CORT. Nisa Investment Advisors LLC lifted its holdings in shares of Corcept Therapeutics by 16.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 20,521 shares of the biotechnology company’s stock valued at $714,000 after purchasing an additional 2,877 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its stake in Corcept Therapeutics by 111.8% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 507,967 shares of the biotechnology company’s stock valued at $19,404,000 after buying an additional 268,155 shares during the last quarter. Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Corcept Therapeutics by 1.1% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 56,946 shares of the biotechnology company’s stock valued at $1,982,000 after acquiring an additional 605 shares during the period. Ausbil Investment Management Ltd grew its position in shares of Corcept Therapeutics by 82.6% during the fourth quarter. Ausbil Investment Management Ltd now owns 10,235 shares of the biotechnology company’s stock worth $356,000 after acquiring an additional 4,629 shares during the last quarter. Finally, SG Americas Securities LLC increased its holdings in shares of Corcept Therapeutics by 49.3% in the 4th quarter. SG Americas Securities LLC now owns 13,828 shares of the biotechnology company’s stock valued at $481,000 after acquiring an additional 4,565 shares during the period. Hedge funds and other institutional investors own 93.61% of the company’s stock.

More Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Zacks Research raised its Q4 2027 EPS estimate for CORT to $1.29 from $1.12, and also lifted its Q4 2026 quarterly estimate to $0.49, suggesting some upward revisions to near-term earnings assumptions. Zacks Research Estimates
• Neutral Sentiment: Coverage pieces comparing Corcept’s profitability profile to peers highlight that the company has delivered revenue growth and positive margins, providing context for long-term investors but not removing short-term regulatory/legal overhangs. 247WallStreet Article
• Negative Sentiment: Zacks Research downgraded Corcept from “hold” to “strong sell” and cut several near‑term quarterly EPS forecasts (Q1–Q3 & Q2–Q3 2027 revisions), and trimmed FY2027 to $3.21 from $3.35 — a signal that at least one sell‑side shop expects slower near‑term profitability. Zacks Downgrade / Estimate Changes
• Negative Sentiment: Multiple shareholder‑law firms (Pomerantz, Schall, Hagens Berman, Holzer & Holzer, Levi & Korsinsky, DJS) have opened investigations alleging potential misstatements or nondisclosure tied to the FDA CRL for relacorilant; legal inquiries typically amplify volatility and can lead to settlement costs or distraction. Pomerantz Investigation
• Negative Sentiment: Press coverage notes that Corcept received an FDA Complete Response Letter for relacorilant (announced Dec. 31), which triggered a sharp share decline and is the proximate cause of current investor concern over relacorilant’s approval path and commercial outlook. Hagens Berman / FDA CRL
• Negative Sentiment: At least one price target hit was reported (a ~28% cut in a published target), reflecting downgrades to valuation assumptions following regulatory setbacks. Price Target Cut

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.